Coureau M, Berghmans T
Service de médecine interne, institut Jules-Bordet, université libre de Bruxelles, Bruxelles, Belgique.
Clinique d'oncologie thoracique, institut Jules-Bordet, université libre de Bruxelles, Bruxelles, Belgique.
Rev Mal Respir. 2021 Jan;38(1):74-86. doi: 10.1016/j.rmr.2020.12.002. Epub 2021 Jan 2.
Surgery is the ultimate curative treatment for resectable non-small cell lung cancer (NSCLC). However, the prognosis for operated patients remains disappointing. Multiple randomized studies have shown that administering perioperative chemotherapy improves the prognosis and increases the cure rate by around 3-5%. The purpose of this article is to take stock of the role of perioperative treatments for NSCLC, which can be completely resected. Six questions were evaluated: 1) What is the place of (neo) adjuvant chemotherapy in 2020, among others in the early stages (IB)? 2) Can new chemotherapy agents be combined with a platinum derivative? 3) What is the place of radiochemotherapy for resectable NSCLC? 4) Is there a place for postoperative radiotherapy (PORT)? 5) Is there a place for targeted therapies for resectable NSCLC? 6) What is the place of immunotherapies in the perioperative period?
手术是可切除非小细胞肺癌（NSCLC）的最终治愈性治疗方法。然而，接受手术治疗患者的预后仍然令人失望。多项随机研究表明，围手术期进行化疗可改善预后，并使治愈率提高约3%至5%。本文旨在评估围手术期治疗对可完全切除的NSCLC的作用。评估了六个问题：1）2020年（新）辅助化疗的地位如何，尤其是在早期阶段（IB期）？2）新型化疗药物能否与铂类衍生物联合使用？3）可切除NSCLC的放化疗地位如何？4）术后放疗（PORT）是否有一席之地？5）可切除NSCLC的靶向治疗是否有一席之地？6）免疫疗法在围手术期的地位如何？
Zotero 插件